338 related articles for article (PubMed ID: 16885381)
1. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Macedo LF; Guo Z; Tilghman SL; Sabnis GJ; Qiu Y; Brodie A
Cancer Res; 2006 Aug; 66(15):7775-82. PubMed ID: 16885381
[TBL] [Abstract][Full Text] [Related]
2. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Sonne-Hansen K; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
[TBL] [Abstract][Full Text] [Related]
3. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
4. [Dual effects of androgens on mammary gland].
Brettes JP; Mathelin C
Bull Cancer; 2008 May; 95(5):495-502. PubMed ID: 18541513
[TBL] [Abstract][Full Text] [Related]
5. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Boulay A; Rudloff J; Ye J; Zumstein-Mecker S; O'Reilly T; Evans DB; Chen S; Lane HA
Clin Cancer Res; 2005 Jul; 11(14):5319-28. PubMed ID: 16033851
[TBL] [Abstract][Full Text] [Related]
6. Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Hanamura T; Niwa T; Nishikawa S; Konno H; Gohno T; Tazawa C; Kobayashi Y; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2013 Jun; 139(3):731-40. PubMed ID: 23780684
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
8. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
9. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
[TBL] [Abstract][Full Text] [Related]
10. Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern.
Pérez-Palacios G; Santillán R; García-Becerra R; Borja-Cacho E; Larrea F; Damián-Matsumura P; González L; Lemus AE
J Endocrinol; 2006 Sep; 190(3):805-18. PubMed ID: 17003281
[TBL] [Abstract][Full Text] [Related]
11. Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Núñez NP; Jelovac D; Macedo L; Berrigan D; Perkins SN; Hursting SD; Barrett JC; Brodie A
Clin Cancer Res; 2004 Aug; 10(16):5375-80. PubMed ID: 15328175
[TBL] [Abstract][Full Text] [Related]
12. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells.
Cos S; Martínez-Campa C; Mediavilla MD; Sánchez-Barceló EJ
J Pineal Res; 2005 Mar; 38(2):136-42. PubMed ID: 15683469
[TBL] [Abstract][Full Text] [Related]
13. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells.
Shields-Botella J; Chetrite G; Meschi S; Pasqualini JR
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):1-13. PubMed ID: 15748827
[TBL] [Abstract][Full Text] [Related]
14. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
Foster PA; Chander SK; Newman SP; Woo LW; Sutcliffe OB; Bubert C; Zhou D; Chen S; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Oct; 14(20):6469-77. PubMed ID: 18927286
[TBL] [Abstract][Full Text] [Related]
15. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors.
Shin I; Miller T; Arteaga CL
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1008s-1012s. PubMed ID: 16467117
[TBL] [Abstract][Full Text] [Related]
16. Effects of androgens on aromatase activity and 11C-vorozole binding in granulosa cells in vitro.
Kirilovas D; Naessen T; Bergström M; Bonasera TA; Bergström-Pettermann E; Holte J; Carlström K; Simberg N; Långström B
Acta Obstet Gynecol Scand; 2003 Mar; 82(3):209-15. PubMed ID: 12694114
[TBL] [Abstract][Full Text] [Related]
17. Dihydrotestosterone affects the growth of hormone-unresponsive breast cancer cells: an indirect action.
Di Monaco M; Leonardi L; Gatto V; Gallo M; Brignardello E; Boccuzzi G
Anticancer Res; 1995; 15(6B):2581-4. PubMed ID: 8669827
[TBL] [Abstract][Full Text] [Related]
18. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor alpha.
Maggiolini M; Donzé O; Jeannin E; Andò S; Picard D
Cancer Res; 1999 Oct; 59(19):4864-9. PubMed ID: 10519397
[TBL] [Abstract][Full Text] [Related]
19. Oestrogen formation in breast: clinical and biological importance.
Dowsett M; Detre S; Rowlands M; Grimshaw R
J Endocrinol; 1996 Sep; 150 Suppl():S59-63. PubMed ID: 8943788
[TBL] [Abstract][Full Text] [Related]
20. [Growth inhibition of MCF-7 human breast cancer cells by aromatase inhibitors].
Fukuoka M; Kitawaki J; Yamamoto T; Okada H
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Dec; 43(12):1667-73. PubMed ID: 1836000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
